Compare Sana Biotechnology Inc (SANA) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Charles Schwab Corporation Common Stock — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while Charles Schwab Corporation Common Stock trades at $96.7 (market cap $167.52B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 200.2× Sana Biotechnology Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.32% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Charles Schwab Corporation Common Stock for 85 Days on average.
| SANA | SCHW | |
|---|---|---|
Market Cap | $836.71M | $167.52B |
Volume | 4,507,444 | 6,554,126 |
Sector | Health | Financials |
52-Week High | $5.92 | $113.65 |
52-Week Low | $2.68 | $85.35 |
Typical Hold Time | 23 Days | 85 Days |
Enterprise Value | $749.96M | $153.97B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Charles Schwab (SCHW) trades at $96.87, up 1.35% on the day, with a bearish technical signal but strong fundamentals. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.62 exceeding the $1.56 estimate. Revenue for 2025 reached $23.92 billion, driving a net income margin of 38.79%. Analyst consensus is bullish with a $120.33 price target, and recent news highlights growth in client assets and AI integration for advisors.
The outlook remains positive given strong profitability and market share gains, though technical weakness and interest rate sensitivity pose near-term risks. Earnings momentum and strategic initiatives like the Texas Stock Exchange listing support upside potential, but investors should monitor competitive pressures and macroeconomic volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
